Tarek Alhamad is a Nephrology physician affiliated with Washington University in St. Louis. OpenAlex indexes 157 publications with 3,074 citations (h-index 29).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
4921 Parkview Pl
Div Im Nephrology, Ste 5c
Saint Louis, MO 631101032
Telephone
314-362-7603Registry record last updated 15 Apr 2025.
Industry payments
19 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Novartis Pharmaceuticals CorporationProgram year20258 payments
- SANOFI-AVENTIS U.S. LLCProgram year20254 payments
- Amgen Inc.Program year20254 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cardiovascular
44.5%Statin12.7%Atorvastatin Calcium85%Pravastatin Sodium7%Rosuvastatin Calcium5%Simvastatin3%Part D<11 patientsBeta blocker11.9%Carvedilol72%Metoprolol Tartrate13%Metoprolol Succinate12%Atenolol2%Nebivolol Hcl2%Part D<11 patients+ 10 more classes in this area
Metabolism & gastrointestinal
32.4%Corticosteroid14.6%Prednisone100%Part D≥230 patientsProton pump inhibitor8.9%Pantoprazole Sodium72%Omeprazole25%Esomeprazole Magnesium2%Dexlansoprazole Dr2%Part D<11 patients+ 5 more classes in this area
Anti-infectives
9.8%Short-acting sulfonamides7%Sulfamethoxazole-Trimethoprim100%Part D≥108 patientsCytomegalovirus Nucleoside Analog DNA Polymerase Inhibitor1.6%Valganciclovir Hcl100%Part D≥58 patients+ 4 more classes in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Subthreshold rejection activity in many kidney transplants currently classified as having no rejection
American Journal of Transplantation
2024 - Posoleucel in Kidney Transplant Recipients with BK Viremia
Journal of the American Society of Nephrology
2024 - The association of donor hepatitis C virus infection with 3-year kidney transplant outcomes in the era of direct-acting antiviral medications
American Journal of Transplantation
2023
Similar KOLs
Other experts from the same institution or the same specialty.
Timothy Ley, MD
Washington University in St. Louis
David Gutmann, MD
Washington University in St. Louis
Randall Bateman, MD
Washington University in St. Louis
Victoria Fraser, MD
Washington University in St. Louis
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”